Company intelligence / Profile preview
NS Pharma, Inc.
Paramus, New Jersey, United Statesnspharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NS Pharma has received FDA acceptance for a Biologics License Application (BLA) for deramiocel, an investigational cell therapy for DMD cardiomyopathy, with a PDUFA target date of August 31, 2025. Recent positive long-term data from the HOPE-2 open label extension clinical trial showed deramiocel's potential to slow disease progression and preserve upper limb function in DMD patients. Additionally, the FDA granted Orphan Drug Designation to NS-229 for the treatment of Eosinophilic Granulomatosis with Polyangiitis in April 2025.
- Therapeutic areas
- CardiovascularImmunologyOncologyRare DiseasesNeurology
- Modalities
- Cell therapyExon-skipping technologyJAK1 inhibitionAntisense oligonucleotides (ASO)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Capricor Therapeutics, Inc. (exclusive distribution agreement for deramiocel in the U.S.)MiNA Therapeutics (collaboration on RNAa therapeutics for rare neurological disorders)
Beyond the preview
Go deeper on NS Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NS Pharma, Inc..